نتایج جستجو برای: kras

تعداد نتایج: 7276  

2017
Weiran Liu Yuesong Yin Jun Wang Bowen Shi Lianmin Zhang Dong Qian Chenguang Li Hua Zhang Shengguang Wang Jinfang Zhu Liuwei Gao Qiang Zhang Bin Jia Ligang Hao Changli Wang Bin Zhang

As shortened telomeres inhibit tumor formation and prolong life span in a KrasG12D mouse lung cancer model, we investigated the implications of telomerase in Kras-mutant NSCLC. We found that Kras mutations increased TERT (telomerase reverse transcriptase) mRNA expression and telomerase activity and telomere length in both immortalized bronchial epithelial cells (BEAS-2B) and lung adenocarcinoma...

2012
SHOZO MIYANO KISABURO HANAZAWA TOSHIAKI KITABATAKE MINORU FUJISAWA KUNIAKI KOJIMA

We investigated the effectiveness of peptide nucleic acid (PNA) clamp PCR for detecting KRAS mutations in peripheral blood samples of colorectal cancer (CRC) patients. We compared KRAS point mutations between tumour tissue and blood samples. Forty-two patients were included in this study. We observed KRAS mutations in formalin-fixed, paraffin-embedded tissues by PCR direct sequencing and in blo...

Journal: :Blood 2009
Jing Zhang Jing Wang Yangang Liu Harwin Sidik Ken H Young Harvey F Lodish Mark D Fleming

KRAS is often mutated in human hematopoietic malignancies, including juvenile myelomonocytic leukemia (JMML) and T-cell lymphoblastic leukemia/lymphoma (TLL/L). However, the exact role and function of oncogenic KRAS mutations in the initiation and progression of JMML and TLL/L remain elusive. Here, we report the use of a mouse bone marrow transplantation model to study oncogenic Kras-induced le...

2018
Wei Jiang Libing Xiang Xuan Pei Tiancong He Xuxia Shen Xiaohua Wu Huijuan Yang

OBJECTIVE The predictive and prognostic role of KRAS mutations in cervical cancer remains inconclusive. The aim of this study was to explore the clinicopathological and prognostic relevance of KRAS mutations in invasive cervical cancers (ICC). METHODS Reverse transcription polymerase chain reaction (PCR) and Sanger sequencing were employed to detect KRAS mutations in 876 ICC patients. Quantit...

2016
D. P. Modest I. Ricard V. Heinemann S. Hegewisch-Becker W. Schmiegel R. Porschen S. Stintzing U. Graeven D. Arnold L. F. von Weikersthal C. Giessen-Jung A. Stahler H. J. Schmoll A. Jung T. Kirchner A. Tannapfel A. Reinacher-Schick

BACKGROUND To explore the impact of KRAS, NRAS and BRAF mutations as well as KRAS mutation variants in patients with metastatic colorectal cancer (mCRC) receiving first-line therapy. PATIENTS AND METHODS A total of 1239 patients from five randomized trials (FIRE-1, FIRE-3, AIOKRK0207, AIOKRK0604, RO91) were included into the analysis. Outcome was evaluated by the Kaplan-Meier method, log-rank...

2012
Krishna R. Kalari David Rossell Brian M. Necela Yan W. Asmann Asha Nair Saurabh Baheti Jennifer M. Kachergus Curtis S. Younkin Tiffany Baker Jennifer M. Carr Xiaojia Tang Michael P. Walsh High-Seng Chai Zhifu Sun Steven N. Hart Alexey A. Leontovich Asif Hossain Jean-Pierre Kocher Edith A. Perez David N. Reisman Alan P. Fields E. Aubrey Thompson

KRAS mutations are highly prevalent in non-small cell lung cancer (NSCLC), and tumors harboring these mutations tend to be aggressive and resistant to chemotherapy. We used next-generation sequencing technology to identify pathways that are specifically altered in lung tumors harboring a KRAS mutation. Paired-end RNA-sequencing of 15 primary lung adenocarcinoma tumors (8 harboring mutant KRAS a...

2015
A. Orlandi M. Di Salvatore C. Bagalà M. Basso A. Strippoli F. Plastino M.A. Calegari A. Cassano A. Astone C. Barone

INTRODUCTION Oxaliplatin (Oxa) is widely used in metastatic colorectal cancer (mCRC), but currently there are not valid predictors of response to this drug. In the control arms both of OPUS and PRIME studies Oxa seems more active in patients with mCRC with mutated (mt) KRAS than in those with wild type (wt) KRAS. Recently we have retrospectively confirmed this suggestion, therefore we have hypo...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2012
Yu Imamura Teppei Morikawa Xiaoyun Liao Paul Lochhead Aya Kuchiba Mai Yamauchi Zhi Rong Qian Reiko Nishihara Jeffrey A Meyerhardt Kevin M Haigis Charles S Fuchs Shuji Ogino

PURPOSE To assess prognostic roles of various KRAS oncogene mutations in colorectal cancer, BRAF mutation status must be controlled for because BRAF mutation is associated with poor prognosis, and almost all BRAF mutants are present among KRAS wild-type tumors. Taking into account experimental data supporting a greater oncogenic effect of codon 12 mutations compared with codon 13 mutations, we ...

2013
Karen Bento Ribeiro Karoline Bento Ribeiro Omar Feres Jose Joaquim Ribeiro da Rocha Liane Rapatoni Sergio Britto Garcia Alfredo Ribeiro Silva Gleici da Silva Castro Perdona Hayala Cristina Cavenague de Souza Saul Isaac Garrido Santillan Harley Francisco de Oliveira Daniela Pretti da Cunha Tirapelli Fernanda Maris Peria

Background KRAS gene mutations play an important role in the carcinogenesis of colorectal tumors. However, studies that have assessed the association between KRAS gene mutation status and disease characteristics report conflicting results. To assess KRAS gene status (mutated or wild-type) and its association with the clinical, epidemiological, and histopathological features of metastatic colore...

2011
Patricia R. Blank Holger Moch Thomas D. Szucs Matthias Schwenkglenks

Purpose: Monoclonal antibodies against the epidermal growth factor receptor (EGFR), such as cetuximab, have led to significant clinical benefits for metastatic colorectal cancer (mCRC) patients but have also increased treatment costs considerably. Recent evidence associates KRAS and BRAFmutations with resistance to EGFR antibodies. We assessed the cost-effectiveness of predictive testing for KR...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید